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Abstract Fibrosarcomas show a high incidence of recurrence
and general resistance to apoptosis. Limiting tumor regrowth
and increasing their sensitivity to chemotherapy and apoptosis
represent key issues in developing more effective treat-
ments of these tumors. Tissue inhibitor of metalloproteinase 1
(TIMP-1) broadly blocks matrix metalloproteinase (MMP)
activity and can moderate tumor growth and metastasis. We
previously described generation of a recombinant fusion pro-
tein linking TIMP-1 to glycosylphophatidylinositol (GPI) an-
chor (TIMP-1-GPI) that efficiently directs the inhibitor to cell
surfaces. In the present report, we examined the effect of
TIMP-1-GPI treatment on fibrosarcoma biology. Exogenous-
ly applied TIMP-1-GPI efficiently incorporated into surface
membranes of human HT1080 fibrosarcoma cells. It inhibited
their proliferation, migration, suppressed cancer cell clone
formation, and enhanced apoptosis. Doxorubicin, the standard
chemotherapeutic drug for fibrosarcoma, was tested alone or
in combination with TIMP-1-GPI. In parallel, the influence of
treatment on HT1080 side population cells (exhibiting tumor
stem cell-like characteristics) was investigated using Hoechst
33342 staining. The sequential combination of TIMP-1-GPI
and doxorubicin showed more than additive effects on apo-
ptosis, while TIMP-1-GPI treatment alone effectively de-
creased “stem-cell like” side population cells of HT1080.
TIMP-1-GPI treatment was validated using HT1080 fibrosar-
coma murine xenografts. Growing tumors treated with repeat-
ed local injections of TIMP-1-GPI showed dramatically
inhibited fibrosarcoma growth and reduced angiogenesis.
Intraoperative peritumoral application of GPI-anchored
TIMP-1 as an adjuvant to surgery may help maintain tumor
control by targeting microscopic residual fibrosarcoma cells
and increasing their sensitivity to chemotherapy
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Introduction
Tumor progression is dependent on interactions between the
tumor and the surrounding stromal tissue. These processes are
mediated in part by a complex system of proteases and
inhibitors including the family of matrix metalloproteinases
(MMPs), and their natural inhibitors, the family of tissue
inhibitors of matrix metalloproteinases (TIMPs). The extra-
cellular matrix (ECM) contains a pool of cytokines, growth
factors and additional components with unknown function.
MMPs not only promote spatial invasion of tumor cells by
degradation of the ECM, but they also help to process prod-
ucts and growth factors that have important signaling func-
tions for gene expression and cell behavior [1]. In this way, a
complex network of proteases/inhibitors is associated with the
invasive front of a progressing cancer.
Inhibition of MMPs has long been proposed as a potential
treatment option for cancers. However, despite promising pre-
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clinical studies, clinical trials with broad-spectrum inhibitors
of MMPs have failed to demonstrate effectiveness [2]. The
lack of efficacy shown with systemic MMP inhibition is in
part linked to the complexity of protease networks. This so-
called protease spam may affect tumor growth locally in a
paracrine fashion and have systemic/endocrine effects [3].
Therefore, more specific and selective strategies of MMP
inhibition need to be developed.
TIMP-1 is a soluble protein that can be occasionally de-
tected on the cell surface through its interaction with surface
proteins and is a natural inhibitor of most MMPs [4–14].
TIMP-1 was originally identified as a naturally occurring
intrinsic barrier to tumor invasion [15, 16]. However, studies
on cancer proliferation and growth have shown both pro- and
anti-tumorigenic effects for TIMP-1 depending on the tumor
and concentration of protein expressed [17–22].
Protein engineering of cell surfaces represents a powerful
tool to study and to expand protein function [23]. Proteins
anchored by glycophosphatidylinositol (GPI), when purified
and added to cells in vitro, are efficiently reincorporated into
their surface membranes [23–26]. Thus, a fusion protein of
TIMP-1-GPI allows the efficient localization of exogenously
added TIMP-1 selectively on to cell membranes independent of
protein–protein interactions [23–26]. This has been previously
shown to result in significant changes in protease stoichiometry
with concomitant alterations in the biological behavior of cells
[26]. These effects include enhanced wound healing in some
instances, and a general inhibition of tumor growth [27].
Recent studies have suggested that a subpopulation of
cancer cells with distinct stem cell-like properties may be
largely responsible for cancer initiation, invasion and metas-
tasis formation. This subpopulation has been referred to as
cancer stem cells (CSCs) [28, 29]. These cells can efflux
chemotherapy drugs, and may thus also account for resistance
of tumors to chemotherapy. CSCs can be defined and isolated
by different methods, including through the expression of
CSC-specific cell surface markers, sphere growth, aldehyde
dehydrogenase (ALDH) activity assays, and by the sorting of
tumor cell side populations detected by exclusion of Hoeschst
33342 dye. Parallel to what is found in ex vivo tumor samples,
side population (SP) cells can also be identified in some tumor
cell lines. These SP cells can also exhibit cancer stem cell-like
characteristics. Alterations in regulatory pathways and gene
networks support the suggestion that SP cells resemble CSCs
and may thus effectively model cell types responsible for
tumor initiation, relapse, metastasis and chemoresistance
[28, 29]. Recently, the importance of these cells in sarcoma,
a tumor entity with high rates of relapse and chemoresistance,
was demonstrated [30].
In the present study, we assessed the effects of exogenous-
ly added TIMP-1-GPI on the biology of fibrosarcoma, includ-
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Cell lines and culture medium
HT1080, a human fibrosarcoma cell line [31], was kept in
DMEM cell culture medium (DMEM low glucose, GIBCO
BRL, Life Technologies GmbH, Eggenstein, Germany)
supplemented with 10 % fetal bovine serum (FBS, Biochrom
AG, Berlin, Germany), 100 units/ml penicillin, and 100 μg/ml
streptomycin (PAN biotech GmbH, Aidenbach, Germany)
and incubated at 37 °C under 5 % CO2. Cells were passaged
by brief trypsination with 0.025 % trypsin (Trypsin/EDTA,
PAN biotech GmbH, Aidenbach, Germany). The cell line was
routinely checked and found to be free of mycoplasma
contamination.
Purification of TIMP-1-GPI protein
The TIMP-1-GPI protein was produced and purified as previ-
ously described [25]. Briefly, human TIMP-1 was cloned from
cDNA using hTIMP-1-specific primers, fused without a trans-
lation stop codon to the GPI-signal sequence cloned from
LFA-3 [23, 32] and subcloned into pEF-DHFR. The expres-
sion plasmid was stably introduced into DHFR-deficient Chi-
nese hamster ovary (CHO) cells and selected as described
[33]. TIMP-1-GPI fusion protein was purified from the
CHO cells by Triton X-100 detergent extraction, followed
by column purification using DEAE, heparin sepharose and
size exclusion [25].
Incorporation of recombinant TIMP-1-GPI into cell
membranes
HT1080 cells (106 cells/ml) were incubated with 7 or 14 ng/ml
of purified TIMP-1-GPI or equivalent recombinant human
TIMP-1 (rhTIMP-1) for 2 h at 37 °C. The cells were then
washed three times with cold PBS and analyzed by flow
cytometry, clone formation, or migration assays.
Fluorescent staining
Surface-associated TIMP-1 protein was detected using human
specific TIMP-1 monoclonal antibody. Incorporated cells
were detached with Trypsin/EDTA and seeded 2500 cells/
well in duplicate Chamber Slide (8-Well Glass Slide, Lab-
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Tek, NUNC, Rochester, NY, USA). After 24 h, the cells were
fixed with 4 % paraformaldehyde for 15 min in room temper-
ature, After PBS washing and Donkey-serum blocking, the
cells were incubated with TIMP-1 monoclonal antibody
(IM32, Anti-TIMP-1 Mouse mAb, Calbiochem, Japan) over-
night in 4 °C. The cells were then washed three times with
PBS, incubated with Goat polyclonal secondary antibody to
mouse IgG-H&L FITC (Abcam, USA), and the nuclei were
stained with DAPI. The slides were observed under fluores-
cent microscope.
Fluorescence-activated cell sorting analysis
Cells were detached with 0.025 % trypsin (Trypsin/EDTA,
PAN biotech GmbH, Aidenbach, Germany) and were kept in
dark and cold blocked with FcR blocking reagent (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) 15 min, and
incubated for 45min on ice with antibodies specific for human
TIMP-1(IM32, Anti-TIMP-1 Mouse mAb, Calbiochem, Ja-
pan). Cells were washed three times with 1× PBS, incubated
with FITC-conjugated donkey anti-mouse mAB (Abcam,
USA) for 45 min at 4 °C and Mouse IgG1-FITC (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) as negative
control, then washed three times with 1×PBS and ana-
lyzed using a flow cytometer (FACSCalibur, Becton Dickin-
son and Company, San Jose, CA, USA) and CellQuest
software.
Viability/proliferation assay
The MTT colorimetric assay was used to measure cellular
metabolic activity via NAD(P)H-dependent cellular oxidore-
ductase enzymes which are linked to cellular viability and
proliferation. HT1080 cells (1.0×104) in 200 μl mediumwere
cultured in 96-well plates for 24 h under standard conditions
to yield firmly attached and stably growing cells. After
discarding supernatants, 50 μl of various concentrations of
TIMP-1-GPI (2, 4, 6, 8, 10, 12 and 14 ng/ml), rhTIMP
(14 ng/ml) or vehicle were added and the cells were incubated
for 2 or 4 h. The supernatants were then discarded, and the
cells were cultured with serum-free medium for another 24 h.
Then 100 μl of a 10 % solution of Cell counting kit-8 (CK04-
13, Dojinbo, Kumamoto, Japan) was added. After 2 h incu-
bation at 37 °C, absorbance was measured at 450 nm using
VersaMax Microplate Reader (Molecular Devices, Sunny-
vale, CA, USA). For each experiment, at least six wells were
analyzed per experimental condition.
Clonogenic assay
The ability of tumor cells to form colonies was assessed using
the clonogenic assay. After incorporation with TIMP-1-GPI,
rhTIMP-1 or vehicle, the HT1080 cells were harvested by
trypsinization and seeded as triplicates in 6-well plates at 200
cells per well and allowed to form colonies in an undisturbed,
humidified, 37 °C/5 % CO2 air atmosphere. After 10 days, the
plates were washedwith 1× PBS and cell colonies were stained
with crystal violet solution (Sigma-Aldrich, Steinheim,
Germany). Only colonies containing at least 50 cells were
considered to be viable survivors.
Migration assay
After incorporation with TIMP-1-GPI, HT1080 cells were
cultured in serum-free medium 24 h before the start of the
migration assay. The cells were detached, and 2.5×104 cells/
well cells were seeded to the upper chamber of the migration
assay set (Cell Culture Insert 8.0 μm, BD Falcon, NJ, USA).
The bottom chamber was filled with 10% FBSmedium. After
6 h of incubation, the cells on the upper surface of the filters
were completely removed by wiping with a cotton swab, as
monitored visually under high magnification. The chambers
were washed 3 times with PBS and fixed with 4 % Parafor-
maldehyde, then detected by 1 mg/ml crystal violet dye. Cells
that had transmigrated the lower surface of the chambers were
counted under a microscope at a magnification of ×200. The
migrated cell number was determined by three randomized
fields of high magnification.
Apoptosis assay
After treatment with TIMP-1-GPI or rhTIMP, the cells were
pelleted and resuspended in staining solution (Annexin-V-FITC-
labeling reagent and PI in PBS buffer) for 15 min at room
temperature as manufacturer suggested (Annexin-V-FITC kit,
MACS Miltenyi Biotec, Bergisch Gladbach, Germany). The
cells were then analyzed by flow cytometry (BD FACSCalibur,
Becton Dickinson and Company, New Jersey, USA) and
CellQuest software. Doxorubicin hydrochloride (D1515-
10MG, Sigma-Aldrich, USA) was added at a concentration of
1 ng/ml to the fibrosarcoma cell line HT1080 for 24 h.
Flow cytometry analysis for side population cells
The ability to discriminate SP cells is based on the differential
efflux of Hoechst 33342 by multi-drug-like ATP-binding
cassette (ABC) transporters. Single-cell suspensions of
HT1080 untreated or treated for 2 h with TIMP-1-GPI at
14 ng/mL were stained with 2.5 μg/ml Hoechst 33342 (Sig-
ma-Aldrich GmbH, Steinheim, Germany) for 60 min at
37 °C. 225uM Verapamil hydrochloride (Sigma-Aldrich
GmbH, Steinheim, Germany) was used to block the ABC
transporters as control. Propidium iodide (10 μg/ml) was
used to discriminate viable and nonviable cells. Cells were
analyzed with a LSR II flow cytometer (BD, Heidelberg,
Germany) equipped with 20-mW, 355 nm UV laser. Hoechst
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blue fluorescence was measured with a 450/50BP and Hoechst
red with a 670/30BP filter.
In vivo tumor model
Female 6–10-week-old BALB/c nu/nu mice were purchased
from Charles River Inc. (Sulzfeld, Germany). Animals were
exposed to 12-h-light/12-h- darkness cycles, and standard
food and water was provided on request. All of the animal
studies were approved by and conducted in accordance with
the principles of the regulatory agency of the State of Bavaria.
HT1080 cells at a concentration of 1.0×106/200 μl cells were
implanted subcutaneously at the upper dorsal aspect of the
vertebral column under general anesthesia, and the growth
characteristics of the tumor established by monitoring growth
by palpation. When the tumor size had reached approximately
0.5 cm in diameter, the animals were randomized into three
groups and therapy was initiated. Local injections of 250 μl of
TIMP-1-GPI at 14 ng/ml, 14 ng/ml of rhTIMP-1 protein or
vehicle (1× phosphate-buffered saline, PBS, 0.025 % Triton
X-100H) were applied. The injections were made every other
day around and in the middle of the tumor (a total of five
points, 50 μl each) for a total of five treatments over a span of
10 days. At least three mice from each group were sacrificed at
post-injection day 14 and tumors were isolated and measured.
The tumor volume was determined by the following formula,
V=π×length×width×height/6.
Immunohistochemistry
Resultant tumors were formaldehyde-fixed and embedded in
paraffin wax. Then 3-μm serial sections were generated. Tis-
sues were deparaffinized in xylene and rehydrated in a graded
series of ethanol. Endogenous peroxidase was blocked by
incubation with 3 % hydrogen peroxide (H2O2). Antigen
retrieval was performed in antigen retrieval solution (Dako,
USA) in a microwave oven. Endogenous avidin and biotin
were blocked using the Avidin/Biotin Blocking Kit (Vector,
USA). The primary antibodies were diluted in PBS containing
3 % bovine serum albumin (BSA). In addition, the slides were
treated for 20 min with blocking solution (8 % goat serum in
PBS with 3 % BSA) before the primary antibody was applied.
The antibodies used included monoclonal rabbit anti-Ki67
antibody (ab16667, Abcam, USA), polyclonal rabbit anti-
CD31 antibody (ab28364, Abcam, USA). Overnight incuba-
tion with the primary antibodies was followed by incubation
with the biotinylated secondary antibody (goat anti-rabbit, BA-
1000, Vector, USA), and the ABC reagent for signal amplifi-
cation (Vectastain ABC-Peroxidase Kits, PK-4000, Vector,
USA). Between incubation steps, the slides were washed in
TBS buffer. 3,3′-diaminobenzidine (DAB, Dako, USA) was
used to develop color. Slides were counter-stained with hema-
toxylin, and mounted in Kaisers Glycerinegelatine (Merck,
Germany) and coverslips. After immunohistochemical stain-
ing against Ki67, slides were observed under high magnifica-
tion scope (×400). Areas showing the highest Ki67 density
were chosen and photographs were taken. These photographs
were analyzed by Image-J program (NIH, MD, USA). The
Ki67 index were evaluated in a blinded manner and calculated
as Ki67-positive cells divided by all tumor cells in one field.
Statistics
The results are presented as mean±SD for each sample. Sta-
tistical significance was assessed by comparing mean values
using the t test for random samples (IBM SPSS 19.0 for
Windows). p values<0.05 were considered significant.
Results
Enhanced incorporation of TIMP-1 into cell surface by fusion
with a GPI anchor
Fluorescent staining showed incorporation of exogenously
added TIMP-1-GPI into the surface membranes of HT1080
cells. HT1080 cells were incubated with 14 ng/ml of TIMP-1-
GPI or 14 ng/ml rhTIMP-1 control proteins for 2 h. Surface-
associated TIMP-1 protein was then detected using anti-TIMP-
1 monoclonal antibody and fluorescent staining. Control
rhTIMP-1 did not change the fluorescent signal as compared
with vehicle control group (Fig. 1a and c). However, GPI-
anchored TIMP-1 led to a strong surface signal for TIMP-1
(Fig. 1e). This was supported by fluorescence-activated cell
sorting (FACS) analysis, which detected strong surface signal
for TIMP-1 in TIMP-1-GPI treated group (Fig. 1f). However,
addition of rhTIMP-1 or vehicle control did not lead to change
in the FACS shift (Fig. 1b, d). Similar results were obtained for
cells treated with 7 ng/ml TIMP-1-GPI (data not shown)
confirming results from previous studies [23–26].
TIMP-1-GPI inhibits proliferation, clone formation
and migration of HT1080 cells in vitro
Djafarzadeh et al. have previously shown that TIMP-1-GPI
treatment can enhance or suppress cell viability/proliferation
depending on the specific cell types studied [24–27, 34]. The
effect of TIMP-1 surface engineering on HT1080 cells were
determined using MTT assays. Exogenously added TIMP-1-
GPI protein was found to elicit a dose- and time-dependent
inhibition in MTT activity of HT1080 in vitro (Fig. 2a).
Subsequent studies were conducted using either 7 or
14 ng/ml TIMP-1-GPI depending upon the specific assay
performed.
Two hundred vehicle, rhTIMP-1, or TIMP-1-GPI treated
HT1080 cells were seeded in six-well plates. Fourteen days
254 Targ Oncol (2014) 9:251–261
later, the clone formation ability of the cells was evaluated
using crystal violet staining. As compared with the vehicle
control or 7 ng/ml rhTIMP-1 group, 7 ng/ml TIMP-1-GPI
significantly inhibited tumor cell clone formation in vitro
(vehicle control vs. TIMP-1-GPI, 99.0±5.0 vs. 13.0±1.7
[mean±SD], *p<0.01; rhTIMP-1 vs. TIMP-1-GPI, 87.7±
4.0 vs. 13.0±1.7, **p<0.01, Fig. 2b).
The effect of TIMP-1-GPI vs. rhTIMP-1 treatment on the
ability of HT1080 cells to migrate was further investigated
using modified Boyden Chamber assays with induced migra-
tion to FBS. Treatment of the HT1080 cells with 7 ng/ml of
TIMP-1-GPI led to a significant suppression of migration,
while no effect was observed with rhTIMP-1 control protein
(vehicle control vs. TIMP-1-GPI, 36.7±12.4 vs. 13.4±2.0,
*p=0.03; rhTIMP-1 vs. TIMP-1-GPI, 34.3±3.7 vs. 13.4±2.0,
**p=0.001; Fig. 2c).
Treatment of HT1080 cells with TIMP-1-GPI enhances
apoptosis
The influence of TIMP-1-GPI treatment on the apoptosis rate
of fibrosarcoma cells was assessed using Annexin-V FACS
assays. In the vehicle control group, the percentage of apo-
ptotic cells was detected as 2.18±0.10 %. Treatment
with rhTIMP-1 did not alter the percentage of apoptotic
cells significantly (3.08±1.18 %, p=0.26). However,
the apoptotic cell percentage increased to 5.13±1.29 %
after treatment with TIMP-1-GPI group, which was sig-
nificantly increased as compared to the vehicle control group
(*p=0.017; Fig. 3a).
To determine the effect of TIMP-1-GPI treatment on the
susceptibility of fibrosarcoma to chemotherapy, doxorubicin,





of GPI-anchored TIMP-1 protein
into cell membranes, purified
TIMP-1-GPI, rhTIMP-1 or
vehicle control reagent was added
to HT1080 cells. TIMP-1 was
detected on the cell surface by
fluorescent staining and FACS
analysis. a, b Vehicle control
group showed no surface signal
for TIMP-1; c, d rhTIMP-1
treated cells showed no surface
signal for TIMP-1; e, f TIMP-1-
GPI treatment lead to strong
TIMP-1 signal on the cell surface
(FACS graphs: gray histograms
represent isotype control stain,
solid red line histograms
represent the anti-TIMP-1
antibody staining)
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was added to the cell culture. In these studies, the therapy
combining TIMP-1-GPI and doxorubicin showed a signifi-
cantly higher percentage of apoptotic cells (TIMP-1-GPI+
doxorubicin: 8.35±0.57 %, vs. vehicle control: 2.03±0.00 %,
**p=0.004; vs. doxorubicin alone: 3.08±1.21 %, *p=0.03;
Fig. 3b) as compared to the control groups of no treatment
or treatment with doxorubicin alone. The rhTIMP-1 control
did not affect susceptibility of fibrosarcoma cells to doxorubi-
cin (TIMP-1-GPI+doxorubicin vs. rhTIMP-1+doxorubicin:
2.71±0.06 %, **p=0.005; Fig. 3b).
Effective inhibition of side population cells in HT1080
by TIMP-1-GPI treatment
The ability of cancer cell subpopulations to exclude Hoechst
33342 dye is used to identify stem cell-like SP. This assay was
able to demonstrate a distinct side population in the
HT1080 fibrosarcoma cells which generally accounted
for 0.54 %±0.17 % of HT1080 cells (mean±SD). While 7 ng/
ml TIMP-1-GPI treatment showed an effect (data not shown),














Fig. 2 GPI-anchored TIMP-1 suppresses proliferation, clone formation
and migration of HT1080 cells in vitro. a The effect of increasing levels
of TIMP-1-GPI (2, 4, 6, 8, 10, 12, 14 ng/ml) or rhTIMP-1 control protein
(14 ng/ml) on the proliferation of HT1080 was measured using a com-
mercial proliferation assay CCK-8 kit; b the effect of vehicle, rhTIMP-1
(7 ng/ml) and TIMP-1-GPI (7 ng/ml) on the clonogenicity of HT1080
was demonstrated using a clone formation assay. Exemplary pictures of
each group are shown in the lower row; c the effect of vehicle, rhTIMP-1
(7 ng/ml) or TIMP-1-GPI (7 ng/ml) on the migration of HT1080 was
demonstrated by a migration assay
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proportion of side population cells as compared to con-
trol vehicle treated HT1080 cells (0.54 %±0.17 % vs.
0.24 %±0.05 %; *p=0.039; Fig. 4).
TIMP-1-GPI inhibits tumor growth in vivo
Subcutaneous HT1080 tumor xenografts were established by
dorsal injection of 1.0×106 HT1080 cells. When the s.c.
tumors reached approximately 0.5 cm in diameter, the tumors
were randomized and treatment with vehicle, rhTIMP-1
(14 ng/ml) and TIMP-1-GPI (14 ng/ml) was initiated. The
samples were injected locally and in equal distribution at four
points surrounding the tumor and into the center of the tumor.
Treatment with TIMP-1-GPI lead to a significant inhibi-
tion in tumor growth as compared to vehicle control and
rhTIMP-1 treatment groups (vehicle control vs. TIMP-1-GPI:
151.9±54.8 cm3 vs. 22.0±25.9 cm3, *p=0.021; rhTIMP-1 vs.
TIMP-1-GPI: 107.9±29.8 cm3 vs. 22.0±25.9 cm3, **p=0.020;
Fig. 5). No significant difference were seen between the vehicle
control group and the group treated with rhTIMP-1 (p=0.29).
Ex vivo analysis shows that TIMP-1-GPI inhibits
tumor proliferation and angiogenesis in vivo
In vitro assays had demonstrated that TIMP-1-GPI treatment
inhibits HT1080 proliferation in a dose- and time-dependent
manner. This was evaluated ex vivo on tissue samples from
the murine xeno tumor model using immunohistochemistry.
Tissue sections were stained with anti-Ki67 and anti-CD31
antibodies to assess effects of TIMP-1-GPI on tumor prolifer-
ation and angiogenesis ex vivo.
The Ki67 index (Ki67+ / total cells) was used to assess the
general proliferation rate of cells within the tissue samples.
As compared to the vehicle control and rhTIMP-1 group, the
Ki67 proliferation index was significantly decreased in the
TIMP-1-GPI treatment group (vehicle control vs. TIMP-1-GPI:
0.55±0.12 vs. 0.20±0.05, *p=0.01; rhTIMP-1 vs. TIMP-1-GPI:
0.61±0.09 vs. 0.20±0.05, **p=0.002; Fig. 6a, b). There was no
significant difference seen between the vehicle control and
rhTIMP-1 groups (p=0.304). Exemplary examples of each
anti-Ki67 stain are provided in Fig. 6b.
Anti-CD31 staining was used to evaluate the microvessel
density of each treatment group. Although there was no sta-
tistical difference demonstrated between these groups with
regards to microvessel density (Supplement Table. 1), assess-
ment of the TIMP-1-GPI treated tumors suggested a trend
towards decreased CD31 positive signals (black arrowheads,
upper row of Fig. 6a).
Discussion
In vivo, the balance between MMPs and TIMPs helps to
determine whether matrix resorption or deposition occurs
[35]. During cancer progression, this balance is shifted towards
the over-expression of proteases. However, broad-spectrum
systemic inhibition of MMPs, e.g., with Marimastat© have
failed to show effectiveness in clinical trials for various reasons
[36].
While the TIMP proteins inhibit MMP activity, and thus,
are capable of modulating tumor growth and metastasis, they
are also multifunctional proteins that modulate cell viability,
proliferation, apoptosis, and angiogenesis. The TIMP family
members have been reported to have conflicting actions on
cancer growth [37]. Treatment with native TIMP-1 can pro-
duce both tumor promoting and inhibiting results. This ap-
pears to vary with the cancer entity examined, the local
concentration of the protein, status of malignant tumor growth
used, and the target organ for metastasis. In general, high
levels of TIMP-1 appear to be necessary for effective
Fig. 3 TIMP-1-GPI induces apoptosis in HT1080 cells. a TIMP-1-GPI
induced more than two-fold the presence of apoptotic cells as compared
with control group, *p<0.05; b TIMP-1-GPI combined with the chemo-
therapeutic drug doxorubicin significantly increased apoptosis in cells as
compared with vehicle control (**p<0.01), doxorubicin alone (*p<0.05)
or rhTIMP-1+doxorubicin (**p<0.01) treatment group. This indicates a
more than additive effect on apoptosis by combining TIMP-1-GPI and
doxorubicin. Apoptotic cells are positive for both Annexin Vand PI [37].
The experiments are representative of at least three replicates. The error
bars indicate standard deviation of the mean
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inhibition of tumor growth, whereas lower systemic levels of
TIMP-1 can promote metastases [38]. We have previously
demonstrated that treatment with TIMP-1-GPI, which leads
to high local expression only on the cell surface, results in
dramatic changes in biological activity of the protein. This is
associated with changes in the surface stoichiometry of the
proteins—relative to that seen with the native protein.
TIMP-1 is a broadly acting soluble inhibitor that can some-
times be detected on the cell surface through its association
with surface-bound proteins [39–41]. Focusing TIMP-1 to the
plasma membrane via a GPI anchor redirects this inhibitor to
the caveola-enriched lipid raft compartment [42]. Exogenous-
ly administered TIMP-1-GPI was shown here to efficiently
insert into the cell membranes of HT1080 cells (Fig. 1)
resulting in inhibition of proliferation, reduced clone forma-
tion and migration, enhanced apoptosis, and reduction in the
level of side population cells.
Although cancer cells can express a broad range of MMPs,
the stromal compartment also responds and displays active
expression of MMPs, e.g., by fibroblasts or endothelial cells
[43]. Therefore, effective cancer treatments based on this
biology should address both the cancer cells and the surround-
ing stromal tissue [44]. Local application of TIMP-1-GPI will
equally influence cancer and stromal compartments and there-
fore meets this therapeutic criterion. In this regard, we have
recently shown that TIMP-1-GPI treatment is not deleterious
to normal tissue, and can even show benefit in in vitro and
in vivo models of wound healing [37].
Fig. 4 TIMP-1-GPI inhibits side population cells. a TIMP-1-GPI treat-
ment led to significant reduction in the level of side population cells as
compared to the vehicle control group (0.54 vs. 0.24 % *p=0.039). As a
calcium channel blocker, verapamil abrogates the dye efflux in almost all
cells and serves as control in this experiment. b Exemplary side popula-
tion FACS analysis of each group is shown (clockwise from upper left:
vehicle control −verapamil; Vehicle control +verapamil; TIMP-1-GPI
14 ng/ml +verapamil; TIMP-1-GPI 14 ng/ml −verapamil)
Fig. 5 Effect of locally applied TIMP-1-GPI on tumor growth in vivo. a
Local injection of TIMP-1-GPI (250μl of 14 ng/ml) significantly inhibited
growth of xenografted HT1080 tumors as compared to rhTIMP-1 (250 μl
of 14 ng/ml) or vehicle control. Injections were made every other day
around and in themiddle of the tumor (a total of five points, 50 μl each) for
a total of 5 treatments over a span of 10 days; b Exemplary photograph of
subcutaneous tumor xenografts at post-injection day 14
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The anti-tumor efficacy of this fusion protein was validated
in vivo using a subcutaneous xenograft model. Injection of
TIMP-1-GPI protein suppressed experimental fibrosarcoma
cell proliferation and decreased overall tumor growth in vivo
with no deleterious effects on normal tissue (Fig. 5). Relat-
ed anti-tumor effects of TIMP-1-GPI treatment were pre-
viously described in experimental colorectal cancer as
well as in melanoma and are supportive of our findings
[24, 34].
Local recurrence of sarcoma after surgical resection repre-
sents a major challenge in treating this tumor entity. Cancer
cells have evolved various mechanisms to evade chemother-
apy including reduced sensitivity to apoptosis [45]. Treatment
of renal cell carcinoma cells with TIMP-1-GPI was previously
shown to increase sensitivity to FAS-mediated apoptosis. In
melanoma, similar increments in sensitivity to apoptosis were
achieved by TIMP-1-GPI treatment when combined with
hyperthermia [24]. In the data presented here, treatment of
fibrosarcoma cells with TIMP-1-GPI also led to enhanced
apoptosis. Hyperthermia, a frequently used treatment modal-
ity in sarcoma, might increase the effectiveness of TIMP-1-
GPI to induce sensitivity to apoptosis even further and it
therefore may enhance chemotherapeutic effectiveness.
In various human cancer cell lines, treatment with high
concentrations of recombinant TIMP-1, or artificial over-
expression of TIMP-1 reduced susceptibility of the cells to
chemotherapy induced apoptosis [46, 47]. Similar results were
seen here in that treatment of HT1080 with low levels of
rhTIMP-1 led to a slightly lower, but statistically not signifi-
cant response to doxorubicin. By contrast, treatment with
nanogram quantities of TIMP-1-GPI lead to enhanced sensi-
tivity of the HT1080 cells to doxorubicin.
Fig. 6 Effect of locally applied TIMP-1-GPI on tumor proliferation and
angiogenesis in vivo. a Exemplary pictures of anti-CD31 and anti-Ki67
antibodies staining. CD31 (black arrowheads) andKi67 positive signals are
less in TIMP-1-GPI treated group; b Ki67 index decreased significantly
after TIMP-1-GPI treatment compared with vehicle control and rhTIMP-1
groups (vehicle control vs. TIMP-1-GPI, *p=0.01; rhTIMP-1 vs. TIMP-1-
GPI, **p=0.002)
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The concept of CSC ascribes the cancer properties of
tumor initiation, progression, metastasis, recurrence and
chemoresistance to a subset of cancer cells that have been
termed CSCs. These cells have the capability to undergo self-
renewal, unlimited proliferation and multi-potentiality. SP
cancer cells are isolated by their ability to exclude Hoechst-
33342-dye via ABC transporters, and are proposed to repre-
sent CSCs in diverse tumor entities [48, 49]. It is thought that
long-term progression free survival in cancer patients will
require effective targeting of CSCs to eliminate these largely
therapy resistant “seed” populations. The SP subpopulation
identified in the human fibrosarcoma cell line HT1080 was
effectively reduced by treatment with TIMP-1-GPI.
Patients suffering from soft tissue sarcoma frequently un-
dergo repeated resections of the tumor due to recurrences. In
these settings, intraoperative peritumoral application of the
therapeutic fusion protein TIMP-1-GPI as an adjuvant to
surgery could help maintain tumor control by targeting mi-
croscopic residual tumor cells in the context of resection. The
direct injection of TIMP-1-GPI could help minimize tumor
growth in non-resectable tumors. Treatment with TIMP-1-
GPI may contribute to the establishment of novel therapeutic
strategies targeting cancer stem cell.
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